Caluke Injection contains Calcium Leucovorin 50 mg, a folinic acid preparation widely used in oncology practice and supportive cancer care. It plays an important role in methotrexate rescue therapy by helping protect healthy cells from the toxic effects of high-dose methotrexate treatment. The injection is administered under medical supervision and is an essential component of various chemotherapy protocols and supportive treatment regimens.

Calcium Leucovorin works by providing a biologically active form of folic acid that helps restore normal cellular function without requiring metabolic activation. This mechanism allows healthy tissues to recover from the effects of certain anticancer medicines while maintaining the effectiveness of cancer treatment. In oncology practice, it is frequently used to reduce toxicity associated with folate antagonist therapies and improve patient tolerance to chemotherapy.

The injection is commonly prescribed as part of high-dose methotrexate rescue therapy and may also be used in combination with Fluorouracil-based chemotherapy regimens for the treatment of colorectal cancer and other malignancies. Additionally, it may be utilized in selected cases of folate deficiency when oral therapy is not suitable. Its versatility and established role in supportive oncology care make it an important medicine in specialized treatment settings.

With the increasing demand for comprehensive cancer treatment and supportive care solutions, Caluke Injection maintains strong relevance in the oncology segment. Its established clinical utility, broad acceptance among oncology specialists, and critical role in chemotherapy support contribute to consistent market demand. The product offers valuable business opportunities and long-term growth potential for retailers and distributors operating within the oncology pharmaceutical market.

Caluke Injection is generally well tolerated when used as directed. Some individuals may experience nausea, vomiting, mild gastrointestinal discomfort, fever, fatigue, injection site reactions, or allergic responses. Serious adverse effects are uncommon but may occur in sensitive individuals and require medical attention.

Caluke Injection is indicated for methotrexate rescue therapy, supportive management during high-dose methotrexate treatment, enhancement of Fluorouracil-based chemotherapy regimens, folate deficiency states, and other conditions as determined by a healthcare professional. It helps reduce treatment-related toxicity and supports healthy cellular recovery.

This medication should be administered only under the supervision of qualified healthcare professionals. The dosage and duration of therapy should be determined according to the patient's clinical condition and treatment protocol. Regular monitoring may be required during oncology treatment. Patients should inform their physician about all ongoing medications and medical conditions before receiving this injection.

Store in a cool, dry place below 25°C, protected from direct sunlight and moisture. Keep the vial in its original packaging until use and out of reach of children. Do not use after the expiry date or if the packaging is damaged, opened, or shows signs of deterioration.